Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.
Clinical and experimental evidence suggests that shock, arthritis, osteoporosis, colitis, leukemia, diabetes, wasting and atherosclerosis are mediated, in part, by interleukin 1 (IL-1). Inhibition of this cytokine has been a strategy for studying disease and for new drug development. A naturally-occurring IL-1 inhibitor (IL-1 receptor antagonist, IL-1ra) that blocks binding of IL-1 to its receptors has been cloned and produced in recombinant organisms. IL-1ra reduces the severity of sepsis, colitis, arthritis and diabetes in animals and is presently being tested in humans with arthritis, shock and myelogenous leukemia.
Dinarello
C A
CA
Tufts University School of Medicine, New England Medical Center, Boston, MA 02111.
Thompson
R C
RC
D000818:Animals; D001168:Arthritis / Q000276:immunology; D004195:Disease Models, Animal; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D007951:Leukemia, Myeloid / Q000276:immunology; D011506:Proteins / Q000276:immunology*; D011971:Receptors, Immunologic / Q000276:immunology; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins / Q000276:immunology; D012769:Shock / Q000276:immunology; D012795:Sialoglycoproteins
C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D011506:Proteins; D011971:Receptors, Immunologic; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; D012795:Sialoglycoproteins